TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.

The FDA has granted full approval to rucaparib (Rubraca) for adults with BRCA-mutated metastatic castration-resistant prostate cancer. The decision is based on a confirmatory analysis of a randomized ...

The annual San Antonio Breast Cancer Symposium was held from Dec. 9 to 12 in San Antonio. Attendees included medical ...

Cedars Sinai gets 30M to establish a specialized BRCA cancer center focusing on research, diagnosis, and treatment in Los Angeles.

Bec Pickering, from Melbourne, has just one wish for her two young daughters after a devastating diagnosis turned her own ...

The FDA has granted standard approval to rucaparib (Rubraca) for the treatment of patients with metastatic ...

The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...

The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...

The FDA converted the PARP inhibitor's 2020 accelerated approval to full approved based on results from the Phase III TRITON3 trial.

A research group at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has identified a candidate ...

The SHARON trial is a phase 1 study testing a new treatment called GO-4 for patients with advanced pancreatic cancer who have ...